imugene ltd
(IMU:Australian Stock Exchange - SEATS)

Last A$0.0060 AUD

Change Today 0.00 / 0.00%

Volume 0.0

IMU On Other Exchanges

Symbol

Exchange

IMU:AU

As of 2:10 AM 05/22/13 All times are local (Market data is delayed by at least 15 minutes).

imugene ltd (IMU) Snapshot

Open A$0.0070		Previous Close A$0.0060
Day High A$0.0070		Day Low A$0.0060
52 Week High 09/17/12 - A$0.02		52 Week Low 05/22/13 - A$0.0060
Market Cap 2.1M		Average Volume 10 Days 96.5K
EPS TTM A$-0.0072		Shares Outstanding 342.3M
EX-Date --		P/E TM --
Dividend --		Dividend Yield --

Current Stock Chart for IMUGENE LTD (IMU)

IMU:AU Historical Stock Quote
IMU:AU Advanced Stock Chart

Related News

No related news articles were found.

imugene ltd (IMU) Related Businessweek News

No Related Businessweek News Found

imugene ltd (IMU) Details

Imugene Limited engages in the research, development, and commercialization of animal health products for pigs and poultry in Australia and internationally. The company’s range of products under development includes vaccines to prevent livestock diseases and productivity enhancers to improve the economics of raising commercial livestock. Its vaccine products for poultry comprise coccidiosis preventative vaccine, poultry productivity enhancer that boosts immune system, avian flu (H5N1) preventative vaccine and diagnostic, avian flu (H7 and H9) preventative vaccine, infectious bursal disease preventative vaccine, and chicken anemia virus preventative vaccine. The company’s vaccine products for pigs consists of porcine reproductive and respiratory disease, porcine circovirus disease, and classical swine fever preventative vaccines, as well as porcine productivity enhancer that boosts immune system. Its Linguet buccal technology system offers a method of drug delivery that allows the active ingredient in a drug to be absorbed directly into the blood stream. Imugene Limited is based in Perth, Australia.

Detailed IMU:AU Company Description...

www.imugene.com

imugene ltd (IMU) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

imugene ltd (IMU) Key Developments

Imugene Ltd. Reports Earnings Results for the Half Year Ended December 31, 2012

Feb 28 13

Imugene Ltd. reported earnings results for the half year ended December 31, 2012. For the period, the company reported revenues of $14,871 and a net loss of $1,235,999 after expensing all research and development costs.

Imugene Ltd. to Report First Half, 2013 Results on Feb 28, 2013

Feb 17 13

Imugene Ltd. announced that they will report first half, 2013 results on Feb 28, 2013

Imugene Ltd. Announces Board Changes

Feb 10 13

Imugene Ltd. has announced changes to its board of directors with the resignation of Mr. Fabio Pannuti, who will stand down as Executive Chairman and from the company's board of directors, effective immediately. Non-Executive Director, Mr. Steve Harris will assume the role of Non-Executive Chairman and Dr. Nicholas Ede has been appointed Executive Director. Mr. Paul Hopper continues in his role as non-Executive Director. Dr. Ede has a record of successfully evolving research concepts to commercial products and processes.